Neurodevelopmental Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Autosomal recessive PRUNE1 mutations are reported to cause a severe neurodevelopmental disorder with microcephaly, hypotonia, and brain malformations.
|
30556349 |
2019 |
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
We outline here the clinical importance of targeting of the Nme-1 (NDPK-A)-Prune-1 protein complex in cancer, where an imbalance in the formation of this protein-protein complex can result in inhibition of tumor progression.
|
29449633 |
2018 |
Developmental Disabilities
|
0.010 |
GeneticVariation
|
group |
BEFREE |
We describe an additional patient with homozygous PRUNE mutation who presented with spinal muscular atrophy phenotype, in addition to the already known brain developmental disorder.
|
29307700 |
2018 |
Medulloblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PRUNE1 is highly expressed in metastatic medulloblastoma group 3, which is characterized by TGF-β signalling activation, c-MYC amplification, and OTX2 expression.
|
29490009 |
2018 |
Childhood Medulloblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PRUNE1 is highly expressed in metastatic medulloblastoma group 3, which is characterized by TGF-β signalling activation, c-MYC amplification, and OTX2 expression.
|
29490009 |
2018 |
Adult Medulloblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PRUNE1 is highly expressed in metastatic medulloblastoma group 3, which is characterized by TGF-β signalling activation, c-MYC amplification, and OTX2 expression.
|
29490009 |
2018 |
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
We outline here the clinical importance of targeting of the Nme-1 (NDPK-A)-Prune-1 protein complex in cancer, where an imbalance in the formation of this protein-protein complex can result in inhibition of tumor progression.
|
29449633 |
2018 |
Malignant neoplasm of stomach
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The h-prune protein is a member of the DHH protein superfamily, and its overexpression in breast, colorectal and gastric cancers correlates with depth of invasion and degree of lymph-node metastasis.
|
17952613 |
2007 |
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The h-prune protein is a member of the DHH protein superfamily, and its overexpression in breast, colorectal and gastric cancers correlates with depth of invasion and degree of lymph-node metastasis.
|
17952613 |
2007 |
Mammary Neoplasms
|
0.010 |
Biomarker
|
group |
LHGDN |
Overexpression of h-prune in breast cancer is correlated with advanced disease status.
|
15671547 |
2005 |
leiomyosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We found amplification of PRUNE in aggressive sarcoma subtypes, such as leiomyosarcomas and malignant fibrous histiocytomas (MFH) as well as in the less malignant liposarcomas.
|
11687967 |
2001 |
liposarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We found amplification of PRUNE in aggressive sarcoma subtypes, such as leiomyosarcomas and malignant fibrous histiocytomas (MFH) as well as in the less malignant liposarcomas.
|
11687967 |
2001 |
Malignant Fibrous Histiocytoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We found amplification of PRUNE in aggressive sarcoma subtypes, such as leiomyosarcomas and malignant fibrous histiocytomas (MFH) as well as in the less malignant liposarcomas.
|
11687967 |
2001 |
Sarcoma
|
0.010 |
Biomarker
|
group |
BEFREE |
We found amplification of PRUNE in aggressive sarcoma subtypes, such as leiomyosarcomas and malignant fibrous histiocytomas (MFH) as well as in the less malignant liposarcomas.
|
11687967 |
2001 |
Malignant neoplasm of soft tissue
|
0.010 |
Biomarker
|
group |
BEFREE |
We found amplification of PRUNE in aggressive sarcoma subtypes, such as leiomyosarcomas and malignant fibrous histiocytomas (MFH) as well as in the less malignant liposarcomas.
|
11687967 |
2001 |
Congenital anomaly of brain
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Autosomal recessive PRUNE1 mutations are reported to cause a severe neurodevelopmental disorder with microcephaly, hypotonia, and brain malformations.
|
30556349 |
2019 |
Neurodegenerative Disorders
|
0.020 |
GeneticVariation
|
group |
BEFREE |
A homozygous canonical splice acceptor site mutation in PRUNE1 is responsible for a rare childhood neurodegenerative disease in Manitoba Cree families.
|
30556349 |
2019 |
Secondary Neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Drosophila prune protein (h-prune) has been proved to play an essential role in regulating tumor metastasis.
|
30665854 |
2019 |
Neurodegenerative Disorders
|
0.020 |
GeneticVariation
|
group |
BEFREE |
This novel feature expands the clinical consequences of PRUNE mutations and allow to converge PRUNE syndrome with previous descriptions of neurodevelopmental/neurodegenerative disorders linked to altered microtubule dynamics.
|
29307700 |
2018 |
Congenital anomaly of brain
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Homozygous or compound heterozygous PRUNE1 mutations were recently identified in five individuals with brain malformations from four families.
|
28211990 |
2017 |
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
The expression of h-prune (human homolog of Drosophila prune protein; HGNC13420), an exopolyphosphatase, is correlated with progression and aggressiveness in several cancers and promotes migration and invasion.
|
27037526 |
2016 |
Neuroblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our study focuses on the role of the Nm23-H1/h-Prune protein complex in Neuroblastoma.
|
23448979 |
2013 |
Central neuroblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our study focuses on the role of the Nm23-H1/h-Prune protein complex in Neuroblastoma.
|
23448979 |
2013 |
Childhood Neuroblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our study focuses on the role of the Nm23-H1/h-Prune protein complex in Neuroblastoma.
|
23448979 |
2013 |
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
The identification of these two modes of inhibition of formation of the nm23-H1-h-prune protein complex pave the way toward new challenges, including translational studies using IC261 or this competitive peptide 'in vivo' to inhibit cellular motility induced by nm23-H1-h-prune complex formation during progression of breast cancer.
|
17906697 |
2008 |